Table 2.
Comparison summary of previous cases of Sjögren's syndrome complicated with clinicopathologic features of TAFRO syndrome.
| Authors | Iwanaga et al. | Fujimoto et al. | Takasawa et al. | Li et al. | Kojima et al. | Our case | ||
|---|---|---|---|---|---|---|---|---|
| Sjögren's syndrome | Histopathology | + | + | ND | ND | ND | ND | |
| Oral examination | + | Scintigraphy | ND | ND | ND | + | ||
| Ocular examination | + | + | + | ND | ND | − | ||
| Anti-Ro/SS-A antibody | + | + | + | + | + | + | ||
| Anti-La/SS-B antibody | − | + | − | ND | + | + | ||
| TAFRO syndrome | Major categories | Anasarca | + | + | + | + | + | + |
| Thrombocytopenia | + | + | + | + | + | + | ||
| Systemic inflammation | + | + | + | + | + | + | ||
| Minor categories | Histology of lymph node biopsy | − | + | + | + | + | ND | |
| Reticulin myelofibrosis | + | + | + | + | ND | − | ||
| Mild organomegaly | + | + | + | + | + | + | ||
| Renal insufficiency | − | + | + | + | ND | ± | ||
| Treatments | PSL, CyA | PSL | PSL, CyA | Siltuximab, PSL, RTX, CY, vincristine | PSL | PSL, CyA, eltrombopag | ||
CY, cyclophosphamide; CyA, cyclosporine; PSL, prednisolone; RTX, rituximab; ND, not determined.